Stock Analysis
Nurix Therapeutics, Inc. (NRIX) Stock Analysis
Nurix Therapeutics, Inc. (NRIX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Nurix Therapeutics, Inc. (NRIX) currently has an AIQ Score of 65/100, indicating a bullish setup. Value is the strongest factor at 94/100. Risk is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NRIX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $15.48 |
| AIQ Score | 65/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $1.73B |
| P/E Ratio (TTM) | 6.17 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $4.93 |
| Revenue (Q3 FY2026) | $673.06M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.06 |
| Volume | 1.39M |
| 52-week range | $12.01-$28.23 |
| RSI 14 | 26.77 |
| 50-Day SMA | $23.27 |
| 200-Day SMA | $20.13 |
| Analyst Price Target | $33.63 |
| Next Earnings | Jan 27, 2027 |
NRIXNurix Therapeutics, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum50
- Value94
- Quality78
- Risk resilience40
- Sentiment—
NRIX Stock Analysis Summary
Nurix Therapeutics, Inc. (NRIX) currently has an AIQ Score of 65/100, indicating a bullish setup. Value is the strongest factor at 94/100. Risk resilience is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, NRIX has AIQ Score of 65/100 with Value base of 94/100 and fading Risk resilience at 40/100. Wait for component alignment before adding exposure.
Value (94/100) leads while Risk resilience (40/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.77% stock move · NRIX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NRIX Bullish or Bearish Right Now?
NRIX currently has a bullish overall setup. Value is the strongest factor at 94/100, while Risk Resilience is weakest at 40/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 78/100.
- - Analyst target implies +117.22% upside from the latest quote.
- - Risk Resilience is weak at 40/100.
- - Price is -23.09% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (37 vs 6).
Current Consensus
NRIX's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 3 neutral, and 37 sell votes. NRIX's 14-day RSI is 26.77, which places the stock in an oversold momentum range. NRIX's beta is 1.06, indicating market sensitivity broadly in line with the market.
What Changed in NRIX?
The largest recent change in NRIX is Momentum moving down by 25.0 points over the available 7-day comparison window. Value remains the strongest visible factor.
What Would Change the NRIX Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NRIX Decision Framework
Public evidence layers, setup checks, and risk context for Nurix Therapeutics, Inc..
Nurix Therapeutics, Inc. (NRIX) Stock Analysis
Nurix Therapeutics, Inc. has an AIQ Score of 65/100 in a Bullish regime. Value is strongest at 94/100. Beta is 1.06, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NRIX is in a Bullish AIQ regime with score 65/100. |
| Signal Conflict | The primary conflict is that value leads at 94/100 while risk lags at 40/100. |
| Factor Evidence | Momentum 50/100 · Value 94/100 · Quality 78/100 · Risk 40/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Value is the strongest factor at 94/100.
Momentum is 50/100 and RSI (14) is 26.8.
NRIX is in a Bullish regime at 65/100.
Risk factor is 40/100 with beta 1.06 and annual volatility 67.3%.
Current conflict: value leads at 94/100 while risk lags at 40/100.
NRIX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NRIX Fundamentals
NRIX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NRIX Technical Analysis
NRIX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NRIX Stock Catalysts
Track NRIX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NRIX Dividend Analysis
NRIX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NRIX Financial Data
NRIX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NRIX Risk Analysis
NRIX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NRIX Stock News
NRIX stock news, market tone, recent headlines, and catalyst context.
NRIX vs Biotechnology Peers
Current peer cohort: NRIX · NVAX · OCUL · OMER · ONC. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NRIX Current stock | 65/100 | 94/100 | 50/100 | 40/100 | 0.64 | 67.30% | Current |
| NVAX Novavax, Inc. | — | — | 77/100 | 38/100 | 0.56 | 73.62% | NRIX vs NVAX |
| OCUL Ocular Therapeutix, Inc. | 38/100 | 41/100 | 34/100 | 36/100 | -0.45 | 76.10% | NRIX vs OCUL |
| OMER Omeros Corporation | 64/100 | 73/100 | 79/100 | 33/100 | 1.36 | 110.84% | NRIX vs OMER |
| ONC BeOne Medicines AG | 80/100 | 71/100 | 91/100 | 72/100 | 0.42 | 34.16% | NRIX vs ONC |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for NRIX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Aug 31, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NRIX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NRIX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NRIX Stock FAQ
What is NRIX stock price today?
Nurix Therapeutics, Inc.'s current stock price is $15.48. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NRIX bullish or bearish right now?
NRIX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NRIX's market cap?
NRIX's market cap is $1.73B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NRIX's current P/E ratio?
NRIX's current P/E ratio is 6.17 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NRIX's RSI?
NRIX's 14-day RSI is 26.77 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NRIX above its 50-day and 200-day moving averages?
NRIX is -33.47% from its 50-day SMA and -23.09% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NRIX's next earnings date?
NRIX's next earnings date is currently listed as Jan 27, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NRIX pay a dividend?
NRIX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.